Second Affiliated Hospital of Guangzhou Medical University
gzhmu.cnLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
73
Active
45
Phase 3
11
Total enrollment
16,390
Pipeline matrix
Showing 40 of 46 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Ivabradine | — | — | — | — | — | 1 | |
| Lenvatinib | — | — | — | — | 2 | ||
| Checkpoint inhibitor (CPI) such as Pembrolizumab plus chemotherapy | — | — | — | — | — | 1 | |
| Lenvatinib, sintilimab plus TACE | — | — | — | — | — | 1 | |
| Lenvatinib plus TACE | — | — | — | — | — | 1 | |
| PD1/PDL1 inhibitor | — | — | — | — | — | 1 | |
| PD1/PDL1/CTLA4 inhibitors | — | — | — | — | — | 1 | |
| Sin-Bev-TACE | — | — | — | — | — | 1 | |
| Len-TACE | — | — | — | — | — | 1 | |
| Len+DEB-TACE+HAIC | — | — | — | — | — | 1 | |
| Len+DEB-TACE | — | — | — | — | — | 1 | |
| ipilimumab+pembrolizumab or ipilimumab+durvalumab, idarubicin, bevacizumab | — | — | — | — | — | 2 | |
| ipilimumab, pembrolizumab, durvalumab, idarubicin, bevacizumab | — | — | — | — | — | 2 | |
| LEN+SIN+DEB-TACE+HAIC | — | — | — | — | — | 1 | |
| LEN+SIN+DEB-TACE | — | — | — | — | — | 1 | |
| Semaglutide | — | — | — | — | — | 1 | |
| Sitagliptin | — | — | — | — | — | 1 | |
| Combination of three inhibitors Trametinib, Everolimus and Lenvatinib | — | — | — | — | — | 1 | |
| NRT6003 | — | — | — | — | — | 1 | |
| Lenvatinib plus SIRT | — | — | — | — | — | 1 | |
| Lenvatinib, sintilimab plus SIRT | — | — | — | — | — | 1 | |
| Injection of drug-eluting microspheres with multiple drugs into solid tumors | — | — | — | — | — | 1 | |
| ipilimumab +pembrolizumab +durvalumab | — | — | — | — | — | 1 | |
| DEB-TACE+HAIC | — | — | — | — | — | 1 | |
| DEB-TACE | — | — | — | — | — | 1 | |
| Sin-Bev-SIRT | — | — | — | — | — | 1 | |
| Skin drug prepared with exome originated from stem cell | — | — | — | — | — | 1 | |
| ITNK cell therapy | — | — | — | — | — | 1 | |
| CAR-T cells | — | — | — | — | — | 1 | |
| CAR-T cells targeting GPC3, Mesothelin, Claudin18.2, GUCY2C, B7-H3, PSCA, PSMA, MUC1, TGFβ, HER2, Lewis-Y, AXL, or EGFR | — | — | — | — | — | 1 | |
| DC cell Vaccine | — | — | — | — | — | 1 | |
| Cell therapy for solid tumors | — | — | — | — | — | 1 | |
| Neoantigen Polypeptide Vaccine | — | — | — | — | — | 1 | |
| TCR-T cells | — | — | — | — | — | 1 | |
| TILs and CAR-TILs targeting HER2, Mesothelin, PSCA, MUC1, Lewis-Y, GPC3, AXL, EGFR, Claudin18.2/6, ROR1, GD1, or B7-H3 | — | — | — | — | — | 1 | |
| CpG-ODN | — | — | — | — | — | 1 | |
| Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cells | — | — | — | — | — | 1 | |
| Neoantigen mRNA Vaccine | — | — | — | — | — | 1 | |
| GPC3 and/or TGFβ targeting CAR-T cells | — | — | — | — | — | 1 | |
| RC001 injection-Dose Escalation Cohort | — | — | — | — | — | 1 |
6 more active programs hidden
Next readouts
- 2026-01-09
- 2026-05-31
- 2026-07-31
- 2026-08-01
- 2026-10-31
- 2026-10-31
- 2026-11-01
- 2026-12-31
- 2027-04-30
- 2027-04-30
Top conditions
- Hepatocellular Carcinoma Non-resectable16
- Lung Cancer10
- Solid Tumor, Adult10
- Hepatocellular Carcinoma10
- Liver Cancer6
- Pancreas Cancer4
- Breast Cancer3
- Surgery3
Frequently asked questions about Second Affiliated Hospital of Guangzhou Medical University
- How many clinical trials does Second Affiliated Hospital of Guangzhou Medical University have on ClinicalTrials.gov?
- Second Affiliated Hospital of Guangzhou Medical University is listed as the lead sponsor on 73 clinical trials in ClinicalTrials.gov, 45 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Second Affiliated Hospital of Guangzhou Medical University's trials are in Phase 3?
- 11 of Second Affiliated Hospital of Guangzhou Medical University's trials are in Phase 3, spread across 46 active drug programs.
- What therapeutic areas does Second Affiliated Hospital of Guangzhou Medical University focus on?
- Second Affiliated Hospital of Guangzhou Medical University's most-studied conditions on ClinicalTrials.gov are Hepatocellular Carcinoma Non-resectable, Lung Cancer, Solid Tumor, Adult, Hepatocellular Carcinoma, Liver Cancer.
- When are Second Affiliated Hospital of Guangzhou Medical University's next clinical trial readouts?
- Second Affiliated Hospital of Guangzhou Medical University has 10 upcoming primary-completion readouts tracked here; the soonest is “Lenvatinib, Sintilimab Plus SIRT for Unresectable HCC”, expected around 2026-01-09.